title: Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.
abstract: OBJECTIVE
  The use of cabergoline and coasting are both effective in reducing the risk of ovarian hyperstimulation syndrome (OHSS). Our aim was to compare the effectiveness of cabergoline with coasting to prevent moderate-severe OHSS.
  
  
  METHODS
  Fifty-seven consecutive infertile patients (81 cycles) at risk of developing OHSS were enrolled through our computerized IVF database system. Inclusion criteria were: (i) E2 level on the day of human chorionic gonadotrophin (hCG) greater than 3,500 pg/ml; (ii) patients who underwent luteal long GnRH agonist cycle; (iii) patients who used cabergoline for OHSS prevention; (iv) patients who underwent coasting for OHSS prevention. The cabergoline group constituted 17 patients (26 cycles) who started using 0.5 mg oral cabergoline daily for 8 days on the day of hCG, whereas the coasting group constituted 40 patients (55 cycles) who underwent coasting.
  
  
  RESULTS
  Both groups were comparable regarding the women's mean age, body mass index and duration of infertility. Implantation rate, clinical pregnancy per embryo transfer and miscarriage rates were not different between the two groups. There was no OHSS in the cabergoline group (0 %), whereas there were two OHSS (3.6 %) in the coasting group; however, this difference was not significant.
  
  
  CONCLUSIONS
  In conclusion, 0.5 mg daily use of cabergoline for 8 days beginning from hCG administration is a very effective way to reduce moderate-severe OHSS without sacrificing pregnancy rates in patients at risk of developing OHSS.
authors.affiliation: Department of Obstetrics and Gynecology, Hacettepe University Faculty of Medicine, Ankara, Turkey, dr@ibrahimesinler.com.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Esinler
authors.forename: Gurkan
authors.initials: G
authors.lastname: Bozdag
authors.forename: Lale
authors.initials: L
authors.lastname: Karakocsokmensuer
mesh_terms: D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D016729:Leuprolide / Q000627:therapeutic use; D008137:Longitudinal Studies; D006080:Ovarian Follicle / Q000166:cytology; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D005300:Fertility Agents, Female; D006728:Hormones; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; D000077465:Cabergoline